Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Rhea-AI Summary

Neurocrine Biosciences (NBIX) has announced its participation in two major investor conferences this March. The company's leadership team will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston, and the Leerink Global Healthcare Conference on March 11, 2025, in Miami.

The presentations will be accessible via live webcasts on the company's investor relations website, with replays available for approximately one month after the events. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company specializing in treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments for conditions such as tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids.

News Market Reaction – NBIX

+1.46%

1 alert

+1.46% News Effect

On the day this news was published, NBIX gained 1.46%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March.

• Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45^th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.
• Chief Financial Officer Matt Abernethy and Vice-President of Investor Relations Todd Tushla will present at the Leerink Global Healthcare Conference on Tuesday, March 11, 2025 at 11:20 AM Eastern Time in Miami.

The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes U.S. FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook.   
(*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-march-302385110.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When and where will Neurocrine Biosciences (NBIX) present at investor conferences in March 2025?

NBIX will present at the TD Cowen Conference in Boston on March 4 at 11:10 AM ET and at the Leerink Conference in Miami on March 11 at 11:20 AM ET.

How can investors access NBIX's March 2025 conference presentations?

Investors can access live webcasts through Neurocrine's website (www.neurocrine.com) under the Investors section, with replays available for approximately one month.

Which executives will represent NBIX at the TD Cowen Healthcare Conference 2025?

CEO Kyle Gano, CFO Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen conference.

What are the main FDA-approved treatments in NBIX's current portfolio?

NBIX has FDA-approved treatments for tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids.

Which therapeutic areas does NBIX focus on for drug development?

NBIX focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.